BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 09, 2002
 |  BioCentury  |  Tools & Techniques

Tuning into stereochemistry

Chiron Corp. has not been shy about striking deals related to its intellectual property for the development of therapeutics for hepatitis C virus (HCV). The company has licensed non-exclusive rights to at least seven pharma companies, a strategy that CHIR has said is based on the difficulty of developing successful HCV therapeutics (see BioCentury, June 24).

But last week, CHIR struck the first HCV deal in which it retained rights to the resulting products, partnering with Enanta Pharmaceuticals Inc....

Read the full 387 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >